1,244 reports of this reaction
1.4% of all OLANZAPINE PAMOATE reports
#16 most reported adverse reaction
HYPERGLYCAEMIA is the #16 most commonly reported adverse reaction for OLANZAPINE PAMOATE, manufactured by H2-Pharma LLC. There are 1,244 FDA adverse event reports linking OLANZAPINE PAMOATE to HYPERGLYCAEMIA. This represents approximately 1.4% of all 88,377 adverse event reports for this drug.
OLANZAPINE PAMOATE has an overall safety score of 85 out of 100. Patients taking OLANZAPINE PAMOATE who experience hyperglycaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERGLYCAEMIA is a less commonly reported adverse event for OLANZAPINE PAMOATE, but still significant enough to appear in the safety profile.
In addition to hyperglycaemia, the following adverse reactions have been reported for OLANZAPINE PAMOATE:
The following drugs have also been linked to hyperglycaemia in FDA adverse event reports:
HYPERGLYCAEMIA has been reported as an adverse event in 1,244 FDA reports for OLANZAPINE PAMOATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERGLYCAEMIA accounts for approximately 1.4% of all adverse event reports for OLANZAPINE PAMOATE, making it a notable side effect.
If you experience hyperglycaemia while taking OLANZAPINE PAMOATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.